Antibody-mediated resolution of light chain-associated amyloid deposits.
about
Light chain (AL) amyloidosis: update on diagnosis and managementAmyloid formation in light chain amyloidosisAmyloid diseases of the heart: current and future therapiesStructural basis for the recognition and cross-linking of amyloid fibrils by human apolipoprotein EInduction of AApoAII amyloidosis by various heterogeneous amyloid fibrilsPhage display and peptide mapping of an immunoglobulin light chain fibril-related conformational epitopeAnnular protofibrils are a structurally and functionally distinct type of amyloid oligomer.Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.Structural classification of toxic amyloid oligomersDirected selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils.A protein puzzle.Conformational Abs recognizing a generic amyloid fibril epitope.Radioimmunodetection of amyloid deposits in patients with AL amyloidosis.A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils.Amyloid adhesins are abundant in natural biofilms.The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies.Micro-imaging of amyloid in mice.Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains.Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibodyCurrent perspectives on cardiac amyloidosis.Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers.Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.Cardiac amyloidosis presenting as recurrent acute coronary syndrome with unobstructed coronary arteries: Case report.The genetics of the amyloidoses: interactions with immunity and inflammation.Drug Insight: emerging therapies for amyloidosis.Role of translational research advancing the understanding of the pathogenesis of light chain-mediated glomerulopathies.Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretinActive and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease.Animal models of human amyloidoses: are transgenic mice worth the time and trouble?Light-chain amyloidosis: SCT, novel agents and beyond.Microbial manipulation of the amyloid fold.Immunoglobulin light chain amyloidosis.Cardiac amyloidosis: where are we today?Novel strategies for the diagnosis and treatment of cardiac amyloidosis.Development and evaluation of agents for targeting visceral amyloid.Generation and characterization of anti-AA amyloid-specific monoclonal antibodies.Immunoglobulin Light Chains Form an Extensive and Highly Ordered Fibril Involving the N- and C-Termini.Current treatment of AL amyloidosis.A model for amyloid fibril formation in immunoglobulin light chains based on comparison of amyloidogenic and benign proteins and specific antibody binding.
P2860
Q21198863-61C7070B-2640-427A-8793-108733D89BB7Q27022257-213041BC-748D-4A61-864B-2602520A35B9Q27023836-34348C77-92E6-4815-98EF-7544E3FAD323Q28252183-7C5683E3-10F4-4570-AF27-F38971106B5BQ28254598-55D16D11-D25D-45AA-BDCB-8E893ED01053Q28388530-B7C24319-B1C9-4099-967D-3AF7E28C3EDBQ30157440-2F4E4AD6-3E9D-4696-B41B-D21562BF4B00Q30370141-F6A944BB-BCE8-4F68-A5C7-63C332646CE3Q30484255-0AFE3DE4-0F62-4EE5-89EB-5A1DDE9250FCQ33307478-9BCD88BD-97E6-4594-9EA8-56FDB37E5E09Q33364937-9A8C21D6-5560-4F9C-A989-BE2EC7657359Q34009881-E0499E4D-ADCF-4122-A242-61D81E8D786CQ34193315-19C66264-7A3C-42D0-A34E-4A43A262E6AEQ34473306-18B742A0-6507-4C3A-862B-6A5F95CB6689Q34541038-26DDB6FB-E4C6-4F9E-9AB2-AADF5A62ECE5Q34711901-D463FC5C-8EEA-4CE2-B12F-418981506031Q35640323-6DE6E1EE-1FF3-4241-BA79-48CCF26FE2B3Q35652050-AB7B75FB-5DC9-4DAC-BA0B-CD815946938DQ35699410-D8FD74F0-851D-4B7B-956C-24C2B50BEDEEQ35785799-ADB26755-7E85-4FC8-A879-BD07A693C004Q35964900-3CF0F50E-BEB5-47B5-9DA3-B93054BAC6A8Q36178075-20F85950-E825-45C2-9714-9182591451D7Q36325334-6AA107D3-9DD3-43ED-ABBA-A2454236891AQ36426658-59FA5742-354B-441D-8C5A-A848076978FDQ36534748-0DC48514-E700-48E8-AD9E-97282634EFB2Q36577160-EB9043AE-3760-4500-9A07-FBA52E589D77Q36857488-4F1FC107-0072-4A57-A229-2C41ADBCF8D1Q36981504-D7EF8FB0-3F57-45BA-B207-D6E22B17FC1DQ37435886-EB803B45-4E33-49D1-A99F-5C701CEE2D8EQ37560167-F3D93690-A0F5-4999-8BE3-5607787C4ABAQ38056010-5D3917AD-DB59-4F6D-9A62-9D23A76C4D43Q38056340-D19B3467-B8E2-4327-9B22-4900EE030D5DQ38172295-7A261826-9858-4138-8F90-AEF1D1C03DF6Q38528406-024952D2-132A-44BB-9136-25198F5FB10BQ38614967-AAB6FF52-0C59-4C31-B8DC-61E1DEA52834Q41814084-011C3908-1AD8-4C45-885B-FEC00BEAC4E1Q41861063-72CA50A0-72D0-4BEE-A7CF-4EBAB9829A16Q42319096-8CF38DDD-4151-4F11-86FE-56F3514A6AE1Q42662215-12ACA03F-2BCF-4C51-886D-810272F71581Q46016224-D7BA1793-B9F7-4C8F-9D0C-9F77EA57AFC3
P2860
Antibody-mediated resolution of light chain-associated amyloid deposits.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Antibody-mediated resolution of light chain-associated amyloid deposits.
@ast
Antibody-mediated resolution of light chain-associated amyloid deposits.
@en
type
label
Antibody-mediated resolution of light chain-associated amyloid deposits.
@ast
Antibody-mediated resolution of light chain-associated amyloid deposits.
@en
prefLabel
Antibody-mediated resolution of light chain-associated amyloid deposits.
@ast
Antibody-mediated resolution of light chain-associated amyloid deposits.
@en
P2093
P2860
P1476
Antibody-mediated resolution of light chain-associated amyloid deposits
@en
P2093
C L Murphy
D A Wolfenbarger
P2860
P304
P356
10.1016/S0002-9440(10)64639-1
P407
P577
2000-10-01T00:00:00Z